Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2293 to 2299 of 2299 entries
Sorted by: Best Match Show Resources per page
Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia.

Critical care explorations

Go RC, Shah R, Nyirenda T, Oe Y, Sarfraz K, Panthappattu JJ, Philip L, Bheeman C, Shah N, Shah S, Dar S, Hung S, Rahman W, Im H, Marafelias M, Omidvari K, Pradhan A, Sadikot S, Rose KM, Sperber SJ, Josephs J.
PMID: 34291223
Crit Care Explor. 2021 Jul 19;3(7):e0493. doi: 10.1097/CCE.0000000000000493. eCollection 2021 Jul.

OBJECTIVES: To determine methylprednisolone's dose, duration, and administration from onset of symptoms and association with 60 days in hospital survival of coronavirus disease 2019 pneumonia.DESIGN: Cohort study.SETTING: Thirteen hospitals in New Jersey, United States during March to June 2020.PATIENTS:...

Cite
Go RC, Shah R, Nyirenda T, et al. Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. Crit Care Explor. 2021;3(7):e0493doi: 10.1097/CCE.0000000000000493.
Go, R. C., Shah, R., Nyirenda, T., Oe, Y., Sarfraz, K., Panthappattu, J. J., Philip, L., Bheeman, C., Shah, N., Shah, S., Dar, S., Hung, S., Rahman, W., Im, H., Marafelias, M., Omidvari, K., Pradhan, A., Sadikot, S., Rose, K. M., Sperber, S. J., & Josephs, J. (2021). Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. Critical care explorations, 3(7), e0493. https://doi.org/10.1097/CCE.0000000000000493
Go, Ronaldo C, et al. "Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia." Critical care explorations vol. 3,7 (2021): e0493. doi: https://doi.org/10.1097/CCE.0000000000000493
Go RC, Shah R, Nyirenda T, Oe Y, Sarfraz K, Panthappattu JJ, Philip L, Bheeman C, Shah N, Shah S, Dar S, Hung S, Rahman W, Im H, Marafelias M, Omidvari K, Pradhan A, Sadikot S, Rose KM, Sperber SJ, Josephs J. Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. Crit Care Explor. 2021 Jul 19;3(7):e0493. doi: 10.1097/CCE.0000000000000493. eCollection 2021 Jul. PMID: 34291223; PMCID: PMC8291358.
Copy Download .nbib Format: NLM
Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset.

Case reports in oncology

Aoki S, Yasui M, Tajirika H, Terao H, Funahashi M, Ohta J.
PMID: 33564288
Case Rep Oncol. 2020 Dec 17;13(3):1490-1494. doi: 10.1159/000511567. eCollection 2020.

An 85-year-old female was admitted to our hospital for left ureteral cancer and para-aortic lymph node metastasis. To control hematuria, a laparoscopic retroperitoneal nephroureterectomy was performed, and papillary urothelial carcinoma (pT3b) was found. To treat para-aortic lymph node metastasis,...

Cite
Aoki S, Yasui M, Tajirika H, et al. Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset. Case Rep Oncol. 2020;13(3):1490-1494doi: 10.1159/000511567.
Aoki, S., Yasui, M., Tajirika, H., Terao, H., Funahashi, M., & Ohta, J. (2020). Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset. Case reports in oncology, 13(3), 1490-1494. https://doi.org/10.1159/000511567
Aoki, Shuntaro, et al. "Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset." Case reports in oncology vol. 13,3 (2020): 1490-1494. doi: https://doi.org/10.1159/000511567
Aoki S, Yasui M, Tajirika H, Terao H, Funahashi M, Ohta J. Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset. Case Rep Oncol. 2020 Dec 17;13(3):1490-1494. doi: 10.1159/000511567. eCollection 2020. PMID: 33564288; PMCID: PMC7841730.
Copy Download .nbib Format: NLM
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study.

Rheumatology (Oxford, England)

Mahmoud K, Zayat AS, Yusof MYM, Dutton K, Teh LS, Yee CS, D'Cruz D, Ng N, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, Vital EM.
PMID: 33792659
Rheumatology (Oxford). 2021 Nov 03;60(11):5194-5204. doi: 10.1093/rheumatology/keab288.

OBJECTIVES: To determine whether SLE patients with inflammatory joint symptoms and US synovitis/tenosyovitis achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objectives included identification of clinical features predicting US synovitis/tenosynovitis.METHODS: In a longitudinal multicentre...

Cite
Mahmoud K, Zayat AS, Yusof MYM, et al. Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford). 2021;60(11):5194-5204doi: 10.1093/rheumatology/keab288.
Mahmoud, K., Zayat, A. S., Yusof, M. Y. M., Dutton, K., Teh, L. S., Yee, C. S., D'Cruz, D., Ng, N., Isenberg, D., Ciurtin, C., Conaghan, P. G., Emery, P., Edwards, C. J., Hensor, E. M. A., & Vital, E. M. (2021). Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford, England), 60(11), 5194-5204. https://doi.org/10.1093/rheumatology/keab288
Mahmoud, Khaled, et al. "Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study." Rheumatology (Oxford, England) vol. 60,11 (2021): 5194-5204. doi: https://doi.org/10.1093/rheumatology/keab288
Mahmoud K, Zayat AS, Yusof MYM, Dutton K, Teh LS, Yee CS, D'Cruz D, Ng N, Isenberg D, Ciurtin C, Conaghan PG, Emery P, Edwards CJ, Hensor EMA, Vital EM. Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. Rheumatology (Oxford). 2021 Nov 03;60(11):5194-5204. doi: 10.1093/rheumatology/keab288. PMID: 33792659; PMCID: PMC8566203.
Copy Download .nbib Format: NLM
Guillain-Barre syndrome with hyperreflexia: A variant.

Journal of pediatric neurosciences

Singhal V, Bhat KG.
PMID: 22408668
J Pediatr Neurosci. 2011 Jul;6(2):144-5. doi: 10.4103/1817-1745.92844.

Guillain-Barre syndrome (GBS) is a common cause of acute peripheral neuropathy and is characterized by hyporeflexia or areflexia. Hyperreflexia has been rarely reported with acute motor axonal neuropathy. A 10-year-old boy presented with asymmetrical weakness of upper and lower...

Cite
Singhal V, Bhat KG. Guillain-Barre syndrome with hyperreflexia: A variant. J Pediatr Neurosci. 2011;6(2):144-5doi: 10.4103/1817-1745.92844.
Singhal, V., & Bhat, K. G. (2011). Guillain-Barre syndrome with hyperreflexia: A variant. Journal of pediatric neurosciences, 6(2), 144-5. https://doi.org/10.4103/1817-1745.92844
Singhal, Vikram, and Bhat, Kamalakshi G. "Guillain-Barre syndrome with hyperreflexia: A variant." Journal of pediatric neurosciences vol. 6,2 (2011): 144-5. doi: https://doi.org/10.4103/1817-1745.92844
Singhal V, Bhat KG. Guillain-Barre syndrome with hyperreflexia: A variant. J Pediatr Neurosci. 2011 Jul;6(2):144-5. doi: 10.4103/1817-1745.92844. PMID: 22408668; PMCID: PMC3296413.
Copy Download .nbib Format: NLM
Summary report of seven cases of COVID-19 infection in renal transplant recipients.

Transplant immunology

Wang T, Qiu T, Yuan Y, Chen Z, Ma X, Zhang L, Jin Z, Zou J, Zhang Y, Zhou J.
PMID: 34384886
Transpl Immunol. 2021 Dec;69:101445. doi: 10.1016/j.trim.2021.101445. Epub 2021 Aug 10.

The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people's lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been...

Cite
Wang T, Qiu T, Yuan Y, et al. Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transpl Immunol. 2021;69:101445doi: 10.1016/j.trim.2021.101445.
Wang, T., Qiu, T., Yuan, Y., Chen, Z., Ma, X., Zhang, L., Jin, Z., Zou, J., Zhang, Y., & Zhou, J. (2021). Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transplant immunology, 69101445. https://doi.org/10.1016/j.trim.2021.101445
Wang, Tianyu, et al. "Summary report of seven cases of COVID-19 infection in renal transplant recipients." Transplant immunology vol. 69 (2021): 101445. doi: https://doi.org/10.1016/j.trim.2021.101445
Wang T, Qiu T, Yuan Y, Chen Z, Ma X, Zhang L, Jin Z, Zou J, Zhang Y, Zhou J. Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transpl Immunol. 2021 Dec;69:101445. doi: 10.1016/j.trim.2021.101445. Epub 2021 Aug 10. PMID: 34384886; PMCID: PMC8352666.
Copy Download .nbib Format: NLM
Corticosteroid Usage in Giant Cell Arteritis.

Neuro-ophthalmology (Aeolus Press)

Kanakamedala A, Hussain M, Kini A, Al Othman B, Lee AG.
PMID: 33762783
Neuroophthalmology. 2020 Jul 16;45(1):17-22. doi: 10.1080/01658107.2020.1767656. eCollection 2021.

Giant cell arteritis (GCA) is a condition that can cause irreversible visual loss if untreated. While corticosteroids remain the mainstay of treatment to prevent visual loss, the type, dose, route, and duration of corticosteroid treatment of GCA remain controversial....

Cite
Kanakamedala A, Hussain M, Kini A, et al. Corticosteroid Usage in Giant Cell Arteritis. Neuroophthalmology. 2020;45(1):17-22doi: 10.1080/01658107.2020.1767656.
Kanakamedala, A., Hussain, M., Kini, A., Al Othman, B., & Lee, A. G. (2021). Corticosteroid Usage in Giant Cell Arteritis. Neuro-ophthalmology (Aeolus Press), 45(1), 17-22. https://doi.org/10.1080/01658107.2020.1767656
Kanakamedala, Amritha, et al. "Corticosteroid Usage in Giant Cell Arteritis." Neuro-ophthalmology (Aeolus Press) vol. 45,1 (2021): 17-22. doi: https://doi.org/10.1080/01658107.2020.1767656
Kanakamedala A, Hussain M, Kini A, Al Othman B, Lee AG. Corticosteroid Usage in Giant Cell Arteritis. Neuroophthalmology. 2020 Jul 16;45(1):17-22. doi: 10.1080/01658107.2020.1767656. eCollection 2021. PMID: 33762783; PMCID: PMC7946056.
Copy Download .nbib Format: NLM
Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone.

Journal of clinical medicine

Belhassen-García M, Sánchez-Puente A, Dorado-Díaz PI, López-Bernús A, Sampedro-Gómez J, Azibeiro-Melchor R, Marcano-Millán E, Rodríguez-Alonso B, Sánchez-Barrado ME, Hernández-García I, Madruga I, Hernández-Pérez G, Carbonell C, García-Aparicio J, Burgos L, López-Sánchez E, Reina C, Ramón AM, Cestero-Ramírez L, Boumhir F, Encinas-Sánchez D, Sánchez-Ledesma M, Herráez J, Araoz P, Sánchez-Crespo MJ, Rodríguez-Rodríguez S, Rodríguez-Gude AE, Sánchez-Hernández MV, Borrás R, Sagredo-Meneses V, Sánchez PL, Marcos M, Martín-Oterino JÁ.
PMID: 35011938
J Clin Med. 2021 Dec 30;11(1). doi: 10.3390/jcm11010198.

BACKGROUND: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose corticosteroid pulse therapy and TCZ...

Cite
Belhassen-García M, Sánchez-Puente A, Dorado-Díaz PI, et al. Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone. J Clin Med. 2021;11(1)doi: 10.3390/jcm11010198.
Belhassen-García, M., Sánchez-Puente, A., Dorado-Díaz, P. I., López-Bernús, A., Sampedro-Gómez, J., Azibeiro-Melchor, R., Marcano-Millán, E., Rodríguez-Alonso, B., Sánchez-Barrado, M. E., Hernández-García, I., Madruga, I., Hernández-Pérez, G., Carbonell, C., García-Aparicio, J., Burgos, L., López-Sánchez, E., Reina, C., Ramón, A. M., Cestero-Ramírez, L., Boumhir, F., Encinas-Sánchez, D., Sánchez-Ledesma, M., Herráez, J., Araoz, P., Sánchez-Crespo, M. J., Rodríguez-Rodríguez, S., Rodríguez-Gude, A. E., Sánchez-Hernández, M. V., Borrás, R., Sagredo-Meneses, V., Sánchez, P. L., Marcos, M., & Martín-Oterino, J. �. �. (2021). Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone. Journal of clinical medicine, 11(1), . https://doi.org/10.3390/jcm11010198
Belhassen-García, Moncef, et al. "Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone." Journal of clinical medicine vol. 11,1 (2021). doi: https://doi.org/10.3390/jcm11010198
Belhassen-García M, Sánchez-Puente A, Dorado-Díaz PI, López-Bernús A, Sampedro-Gómez J, Azibeiro-Melchor R, Marcano-Millán E, Rodríguez-Alonso B, Sánchez-Barrado ME, Hernández-García I, Madruga I, Hernández-Pérez G, Carbonell C, García-Aparicio J, Burgos L, López-Sánchez E, Reina C, Ramón AM, Cestero-Ramírez L, Boumhir F, Encinas-Sánchez D, Sánchez-Ledesma M, Herráez J, Araoz P, Sánchez-Crespo MJ, Rodríguez-Rodríguez S, Rodríguez-Gude AE, Sánchez-Hernández MV, Borrás R, Sagredo-Meneses V, Sánchez PL, Marcos M, Martín-Oterino JÁ. Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone. J Clin Med. 2021 Dec 30;11(1). doi: 10.3390/jcm11010198. PMID: 35011938; PMCID: PMC8746130.
Copy Download .nbib Format: NLM
Showing 2293 to 2299 of 2299 entries